{
  "id": "5fdb42e7a43ad31278000026",
  "type": "factoid",
  "question": "Which is the main gene signature in Systemic Lupus Erythematosus (SLE)?",
  "ideal_answer": "Systemic Lupus Erythematosus (SLE) has a type I interferon (IFN) gene signature.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/23400715",
    "http://www.ncbi.nlm.nih.gov/pubmed/15593221",
    "http://www.ncbi.nlm.nih.gov/pubmed/18075793",
    "http://www.ncbi.nlm.nih.gov/pubmed/27009916",
    "http://www.ncbi.nlm.nih.gov/pubmed/19790071",
    "http://www.ncbi.nlm.nih.gov/pubmed/30745462",
    "http://www.ncbi.nlm.nih.gov/pubmed/31130331",
    "http://www.ncbi.nlm.nih.gov/pubmed/25861459",
    "http://www.ncbi.nlm.nih.gov/pubmed/31044165",
    "http://www.ncbi.nlm.nih.gov/pubmed/28130918",
    "http://www.ncbi.nlm.nih.gov/pubmed/32334613",
    "http://www.ncbi.nlm.nih.gov/pubmed/17849124",
    "http://www.ncbi.nlm.nih.gov/pubmed/20538795",
    "http://www.ncbi.nlm.nih.gov/pubmed/24598455",
    "http://www.ncbi.nlm.nih.gov/pubmed/31660791",
    "http://www.ncbi.nlm.nih.gov/pubmed/24379124",
    "http://www.ncbi.nlm.nih.gov/pubmed/19479852",
    "http://www.ncbi.nlm.nih.gov/pubmed/15511676",
    "http://www.ncbi.nlm.nih.gov/pubmed/23754736",
    "http://www.ncbi.nlm.nih.gov/pubmed/29644082",
    "http://www.ncbi.nlm.nih.gov/pubmed/23028528",
    "http://www.ncbi.nlm.nih.gov/pubmed/24839407",
    "http://www.ncbi.nlm.nih.gov/pubmed/12642603",
    "http://www.ncbi.nlm.nih.gov/pubmed/24834763",
    "http://www.ncbi.nlm.nih.gov/pubmed/31890206",
    "http://www.ncbi.nlm.nih.gov/pubmed/23083033",
    "http://www.ncbi.nlm.nih.gov/pubmed/30185417",
    "http://www.ncbi.nlm.nih.gov/pubmed/27723281",
    "http://www.ncbi.nlm.nih.gov/pubmed/27094810",
    "http://www.ncbi.nlm.nih.gov/pubmed/21803750",
    "http://www.ncbi.nlm.nih.gov/pubmed/19968664",
    "http://www.ncbi.nlm.nih.gov/pubmed/22242767"
  ],
  "snippets": [
    {
      "text": "The effects of anifrolumab on type I IFN pathway activation were assessed using signal transducer and activator of transcription 1 (STAT1) phosphorylation, IFN-stimulated response element-luciferase reporter cell assays and type I IFN gene signature induction.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29644082",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Randomization was stratified by SLE Disease Activity Index 2000 score (<10 or \u226510), oral corticosteroid dosage (<10 or \u226510 mg/day), and type I IFN gene signature test status (high or low) based on a 4-gene expression assay.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28130918",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "patients with a high IFN signature at baseline ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28130918",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Patients were stratified by disease activity, interferon gene-signature test (high vs low based on the expression of four genes) and geographical region. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27009916",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Our group, using microarray analysis, identified the interferon (IFN) gene signature in pediatric systemic lupus erythematosus (SLE) and has published data that suggest high doses of intravenous corticosteroid treatment may have benefit over strictly oral regimens.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24839407",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this study, we report the presence of IFN activation in SLE bone marrow (BM), as measured by an IFN gene signature, increased IFN regulated chemokines, and direct production of IFN by BM-resident cells, associated with profound changes in B cell development.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24379124",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pronounced alterations in B cell development were noted in SLE in the presence of an IFN signature with a reduction in the fraction of pro/pre-B cells, suggesting an inhibition in early B cell development and an expansion of B cells at the transitional stage.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24379124",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " At baseline, patients had moderate-to-severe disease activity (mean SLE Disease Activity Index score 11.0), and most (75.2%) had a high type I interferon (IFN) gene signature. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400715",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Inhibition of the type I IFN gene signature was sustained during treatment in patients with a high baseline signature. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23400715",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Patient baseline body WT, interferon gene signature from 21 genes, steroid use, and sifalimumab dose were identified as significant covariates for CL, whereas only baseline body WT was a significant covariate for V 1 and peripheral volume of distribution (V 2)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23754736",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These include: type I interferon (IFN) gene signature as a pharmacodynamic marker and potential predictive marker for anti-type I IFN therapy; anti-double stranded DNA as a disease marker and potential predictive marker for flares; the complements and neutrophil signatures as disease marker of SLE",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23083033",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "All SLE B cell populations revealed an interferon (IFN) gene signature previously only reported in unseparated SLE peripheral blood mononuclear cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23028528",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A five gene type I IFN signature was assessed in these subjects to identify subpopulations showing both activation and concordance of the type I IFN pathway in the peripheral blood and disease-affected tissues of each disease and to correlate activation of this pathway in the WB with clinical measurements",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21803750",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "aseline disease activity measurements correlated with a type I IFN gene signature in the WB of subjects with SLE, PM and SSc, as did various serum autoantibody levels in subjects with SLE and DM.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21803750",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Real-time PCR was used to confirm a type I interferon (IFN) gene signature in patients with SLE, and the IFN-regulated proteins PRKRA, IFITM1 and CD69 (P < .0001) were found to be up-regulated in platelets from SLE patients compared with healthy volunteers. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20538795",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In addition, platelets with type I IFN signature could be a novel marker for vascular disease in SLE.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20538795",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "During the trial, we also examined whether overexpression of an IFNalpha/beta-inducible gene signature in whole blood could serve as a pharmacodynamic biomarker to evaluate IFNalpha neutralization and investigated downstream effects of neutralizing IFNalpha on BAFF and other key signaling pathways, i.e., granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-10 (IL-10), tumor necrosis factor alpha (TNFalpha), and IL-1beta, in SLE",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19479852",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "IFNalpha/beta-inducible gene signatures in whole blood are effective pharmacodynamic biomarkers to evaluate anti-IFNalpha mAb therapy in SLE",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19479852",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SLE is characterized by a type-I interferon gene signature.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17849124",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These observations provide a link between dysregulation of apoptosis and phagocytosis and the type-I interferon signature observed in SLE patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17849124",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Of interest, the IFN gene 'signature' correlates with more severe disease. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15511676",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A role for interferon (IFN) in systemic lupus erythematosus (SLE) pathogenesis is inferred from the prominent IFN gene signature (IGS), but the major IFN species and its relationship to disease activity are unknown.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31044165",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Interferon (IFN) signature genes have been shown to be expressed highly in peripheral blood of patients with systemic lupus erythematosus (SLE), especially in the presence of active disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19968664",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: The interferon (IFN) signature is related to disease activity and vascular disease in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) and represents a promising therapeutic target.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30185417",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: There is increased expression of type I interferon (IFN)-regulated proteins in the blood and target tissues of patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22242767",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVES: The interferon (IFN) signature (IS) in patients with systemic lupus erythematosus (SLE) includes over 100 genes induced by type I IFN pathway acti",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25861459",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A role for interferon (IFN) in systemic lupus erythematosus (SLE) pathogenesis is inferred from the prominent IFN gene signature (IGS), but the major IFN species and its relationship to disease activity are unknown. A bi",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31044165",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " group, using microarray analysis, identified the interferon (IFN) gene signature in pediatric systemic lupus erythematosus (SLE) and has published data that suggest high doses of intravenous corticosteroid treatment may have benefit over strictly oral regimens. Additio",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24839407",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTRODUCTION: A hallmark of systemic autoimmune diseases like systemic lupus erythematosus (SLE) is the increased expression of interferon (IFN) type I inducible genes, so-called IFN type I ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24598455",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Patients with systemic lupus erythematosus (SLE) have an increased expression of type I interferon (IFN)-regulated genes (an IFN signature), which is caused by an ongoing production of type I IFNs by plasmacytoid dendritic cells (pDCs). The",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27094810",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " This study investigated serum IL-3 and IFN levels, and a whole blood 'IL-3 gene signature', in human SLE",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31890206",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SION: SLE patients demonstrated increased expression of an IFN response gene signature (75% of patients had an elevated IFN response gene signature) at baseline in ILLUMINATE-1 and ILLUMINATE-2. Subs",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27723281",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SLE patients exhibit increased IFN signatures in their skin secondary to increased production and a robust, skewed IFN response that is regulated by PITX1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30745462",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " An earlier study showed that SLE patients carrying an interferon (IFN) gene expression signature in blood have elevated serum levels of IFN-regulated chemokines",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19790071",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " The role of type I interferon (IFN) in SLE has been demonstrated from the 2000s, by gene expression analyses showing significant over-expression of genes related to type I IFN signalling pathway (IFN signature)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32334613",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The type I interferon (IFN) gene signature and circulating autoantibodies are hallmarks of SLE.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31130331",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Many SLE patients have increased serum levels of IFN-alpha and display an IFN gene expression \"signature\" characterized by strong overexpression of IFN-responsive genes in leukocytes and target tissues.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18075793",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " However, several studies questioned the role of measuring the intensity of IFN signature (IFN score) to chase SLE activity",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32334613",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A bioinformatic approach employing individual IFN species gene signatures to interrogate SLE microarray datasets demonstrates a putative role for numerous IFN species, with prominent expression of IFNB1 and IFNW signatures.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31044165",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "GS test-high patients overexpressed many gene signatures associated with SLE pathogenesis compared with IFNGS test-low patients, reflecting broad immune activation. Th",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31660791",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "I IFN signature could be a novel marker for vascular disease in SLE.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20538795",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Real-time PCR was used to confirm a type I interferon (IFN) gene signature in patients with SLE, and the IFN-regulated proteins PRKRA, IFITM1 and CD69 (P < .0001) were found to be up-regulated in platelets from SLE patients compared with healthy volunteers.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20538795",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "An increased expression of type I IFN-regulated genes, termed IFN signature, has been reported in patients with SLE.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24834763",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Using oligonucleotide microarrays, we now show that active SLE can be distinguished by a remarkably homogeneous gene expression pattern with overexpression of granulopoiesis-related and interferon (IFN)-induced genes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12642603",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: To study the contribution of interferon-alpha (IFNalpha) and IFNgamma to the IFN gene expression signature that has been observed in microarray screens of peripheral blood mononuclear cells (PBMCs) from patients with systemic lupus erythematosus (SLE).METHODS: Quantitative real-time polymerase chain reaction analysis of healthy control PBMCs was used to determine the relative induction of a panel of IFN-inducible genes (IFIGs) by IF",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15593221",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "osus (SLE). Patients with SLE have increased IFN-regulated gene expression pointing towards a possible underlying genetic defect.OBJECTIVES: To determine expression levels of five type I IFN-regulated genes that are highly expressed in SLE in the peripheral blood of patients with CLE and to correlate the expression levels with cutaneous disease activity.METHODS: Peripheral blood was obtained from 10 healthy controls and 30 patients with CLE, incl",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22242767",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Up-regulation of a set of 63 IFN signature genes was seen in 83% of SLE patients and 50% of ILE patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19968664",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "IFN signature, Interferon signature"
}